An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co. announced an increase in its dividend forecasts for the fiscal year ending March 31, 2025, reflecting its commitment to shareholder returns and corporate value growth. The company has achieved revenue stability in its domestic market through its respiratory infection treatments and is expanding its global presence with Cefiderocol. Additionally, Shionogi is advancing its COVID-19 treatment, Ensitrelvir, through clinical trials and regulatory discussions, while benefiting from increased royalties from its HIV franchise. The dividend increase is part of Shionogi’s strategy to enhance shareholder value, supported by its strong financial performance and strategic investments.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, primarily focused on developing and marketing treatments for infectious diseases. Their key products include Xocova, a COVID-19 treatment, and Xofluza, an influenza medication. The company is also involved in the global expansion of Cefiderocol, an antibiotic, and has a growing HIV franchise through ViiV Healthcare Ltd.
YTD Price Performance: 9.91%
Average Trading Volume: 1,483
Technical Sentiment Signal: Sell
Current Market Cap: $14.79B
For a thorough assessment of 4507 stock, go to TipRanks’ Stock Analysis page.